Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
November 07, 2023 08:01 ET
|
Mainz BioMed NV
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
October 31, 2023 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
October 26, 2023 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
October 18, 2023 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
October 11, 2023 08:01 ET
|
Mainz BioMed NV
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
October 05, 2023 08:01 ET
|
Mainz BioMed NV
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
October 04, 2023 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
September 27, 2023 08:01 ET
|
Mainz BioMed NV
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
September 20, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
September 13, 2023 03:01 ET
|
Mainz BioMed NV
Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense) BERKELEY, Calif. and MAINZ, Germany, Sept. 13, 2023 (GLOBE NEWSWIRE) --...